Posttransplant Anemia in Renal Recipients

Posttransplant anaemia is a common and multifactorial complication affecting kidney transplant recipients throughout the early and late post-transplant periods. Early anaemia, occurring within the first six months, often reflects surgical blood loss, haemodilution and iron deficiency, whereas late anaemia may result from chronic graft dysfunction, persistent inflammation, medication effects and micronutrient deficiencies. Immunosuppressive agents, particularly mammalian target of rapamycin (mTOR) inhibitors, can increase erythropoietin resistance, while residual uraemia and allograft rejection provoke inflammatory pathways that suppress erythropoiesis. Persistent anaemia has been linked to reduced exercise capacity, fatigue, diminished quality of life and increased risk of graft loss, cardiovascular complications and mortality. Management strategies centre on identification and correction of reversible causes, iron repletion—oral or intravenous—and use of erythropoiesis-stimulating agents to achieve tailored haemoglobin targets. Despite established guidelines adapted from chronic kidney disease management, anaemia remains underdiagnosed and undertreated in many settings. Emerging evidence underscores the need for transplant-specific protocols that balance optimal haemoglobin control against potential cardiovascular risks. A comprehensive approach encompassing routine monitoring of iron indices, careful immunosuppressive choice and structured anaemia management can improve patient-reported outcomes, graft longevity and overall survival.

Research from Nature Portfolio

Recent investigations into post-transplant iron dynamics reveal that iron status one year after transplantation has a direct impact on long-term kidney outcomes. Studies monitoring ferritin and transferrin saturation levels over several years document an initial decline in transferrin saturation followed by gradual recovery, while ferritin remains depressed. Elevated transferrin saturation above target ranges correlates with a higher incidence of graft failure and significant decline in estimated glomerular filtration rate. These findings suggest that both iron overload and deficiency should be considered in postoperative surveillance, and that tailored iron management may mitigate the risk of chronic allograft deterioration.

Posttransplant Anemia in Renal Recipients publication trend

The graph below shows the total number of articles in posttransplant anemia in renal recipients across all publications each year (not limited to Nature Index journals).

Technical terms

Posttransplant anaemia: A decrease in haemoglobin concentration occurring after kidney transplantation, often defined by World Health Organization thresholds.

Ferritin: A protein that stores iron; serum ferritin reflects total body iron stores but may be elevated in inflammation.

Transferrin saturation (TSAT): The percentage of transferrin bound to iron, used to assess iron availability for erythropoiesis.

Erythropoiesis-stimulating agent (ESA): A medication that stimulates red blood cell production, commonly used to treat anaemia in renal patients.

Estimated glomerular filtration rate (eGFR): A calculated index of kidney function based on serum creatinine, age, sex and race.

Graft failure: Loss of transplanted kidney function requiring return to dialysis or re-transplantation.

References

1. Iron deficiency, anemia, and patient-reported outcomes in kidney transplant recipients. American Journal of Transplantation (2024).
2. Impact of iron status on kidney outcomes in kidney transplant recipients. Scientific Reports (2023).
3. Post-transplant renal anemia: a call to action from a national study in routine clinical practice. Clinical Kidney Journal (2024).
4. Post renal transplant anemia: severity, causes and their association with graft and patient survival. BMC Nephrology (2019).
5. Factors associated with anaemia in kidney transplant recipients in the first year after transplantation: a cross-sectional study. BMC Nephrology (2018).
6. Treatment Options for Anemia in Kidney Transplant Patients: A Review. Kidney Medicine (2023).
7. mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients. Frontiers in Medicine (2022).